Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study
PROVE
A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy
1 other identifier
observational
45
1 country
1
Brief Summary
Since the introduction of vitrectomy in 1971, this procedure has become the third most frequently performed ophthalmic surgery. Approximately 225,000 vitrectomies are performed annually in the United States and indications continue to expand. Known long-term complications of vitrectomy are relatively few and include retinal detachment and cataract formation. Although much has been written in the literature concerning acute rises in intraocular pressure (IOP) in the immediate postoperative period, there is surprisingly little information on long term IOP outcomes after vitrectomy. A recent report by Chang given at the LXII (62) Edward Jackson Memorial Lecture hypothesized a causal relationship between vitrectomy and open-angle glaucoma (OAG) via oxidative stress exacerbated by removal of the crystalline lens. A second report by Luk and colleagues reported similar conclusions in a modified cohort. Both studies, were retrospective in nature and did not perform baseline evaluations to exclude pre-existing glaucoma. Furthermore neither study accounted for natural history. Finally, our analysis has not reproduced similar results. The primary purpose of this study is to analyze the full spectrum of optic nerve and macular changes between vitrectomized study eyes and their non-vitrectomized fellow eyes to control for natural history. Baseline evaluations will include examination by fellowship trained retina and glaucoma specialists, fundus photography, autofluorescence, optical coherence tomography (macula and optic nerve) and automated visual field testing. At 3 month then annually for 5 years after vitrectomy surgery, the cohort will undergo similar evaluation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2010
CompletedFirst Submitted
Initial submission to the registry
July 12, 2010
CompletedFirst Posted
Study publicly available on registry
July 14, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 24, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 24, 2017
CompletedFebruary 23, 2017
February 1, 2017
6.6 years
July 12, 2010
February 20, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Nerve fiber layer and macular changes after vitrectomy
To determine the incidence of nerve fiber layer (NFL) and macular changes after pars plana vitrectomy, characterize their extent and quality, and determine pre-disposing risk factors.
3 month and annually for 5 years after surgery
Secondary Outcomes (2)
Visual field defects
3 month and annually for 5 years after surgery
Open-angle glaucoma
3 month and annually for 5 years after surgery
Eligibility Criteria
Adult patients presenting to ophthalmology practice requiring pars plana vitrectomy
You may qualify if:
- Able to consent and comply for the duration of the study and imaging studies
- Media clarity sufficient for imaging studies
- No previous treatment or surgery that might confound study results in the study or fellow eye
- Pars plana vitrectomy (PPV) indicated for epiretinal membrane (ERM), macular hole (MH), vitreo-macular traction (VMT), and vitreous hemorrhage (VH)
You may not qualify if:
- Unable to consent and/or comply for the duration of the study and imaging studies
- History of the following conditions: Glaucoma or associated conditions, visual field defects, uveitis, age-related macular degeneration (ARMD), prior PPV for retinal detachment, retained lens or dislocated intraocular lens
- Contralateral eye status post PPV or with advanced eye disease serious enough to warrant future PPV - Contralateral eye with condition that may result in choroidal neovascular membrane
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vanderbilt Eye Institute
Nashville, Tennessee, 37203, United States
Related Publications (3)
Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971 Jul-Aug;75(4):813-20. No abstract available.
PMID: 5566980BACKGROUNDChang S. LXII Edward Jackson lecture: open angle glaucoma after vitrectomy. Am J Ophthalmol. 2006 Jun;141(6):1033-1043. doi: 10.1016/j.ajo.2006.02.014.
PMID: 16765671BACKGROUNDLuk FO, Kwok AK, Lai TY, Lam DS. Presence of crystalline lens as a protective factor for the late development of open angle glaucoma after vitrectomy. Retina. 2009 Feb;29(2):218-24. doi: 10.1097/IAE.0b013e31818ba9ca.
PMID: 18936722BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stephen J Kim, MD
Vanderbilt Eye Institute
- STUDY DIRECTOR
Maziar Lalezary, MD
Vanderbilt Eye Institute
- STUDY DIRECTOR
Rahul K Reddy, MD
Vanderbilt Eye Institute
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Ophthalmology
Study Record Dates
First Submitted
July 12, 2010
First Posted
July 14, 2010
Study Start
July 1, 2010
Primary Completion
January 24, 2017
Study Completion
January 24, 2017
Last Updated
February 23, 2017
Record last verified: 2017-02